Partner Sites

Precision Medicine & Companion Diagnostics

Representation of analysis using blood-based biomarkers for Alzheimer's disease.
Updated |3 min read

Blood-Based Biomarkers Are Transforming the Diagnosis of Alzheimer’s Disease

Real-world validation continues to reinforce the utility of blood-based biomarkers in Alzheimer’s disease for earlier and more accurate diagnosis
byMaria-Magdalena Patru, MD, PhD
Clinical lab scientist holding a sample for PTEN protein assessment in prostate cancer.
|2 min read

FDA Clears Roche Test to Identify PTEN Loss in Prostate Cancer, Expanding Access to Targeted Therapy

Roche’s VENTANA PTEN (SP218) IHC companion diagnostic detects PTEN-deficient tumors in prostate adenocarcinoma, helping guide eligibility for TRUQAP (capivasertib) combination treatment in metastatic disease
byToday's Clinical Lab
Cell-free DNA is now being applied across multiple areas of medicine, including prenatal testing, oncology, transplantation, and infectious disease.
|3 min read

What Cell-Free DNA Means for Clinical Laboratories

CAP experts share insights on the clinical utility and evolving role of cfDNA in the clinical laboratory
byGagan Mathur, MD, MBA, CPE, FCAP andPearl Audon, DO
Current biomarkers used to guide immunotherapy decisions have shown limited predictive accuracy in some cancers.
|2 min read

Mayo Clinic, Stanford Develop Blood Test to Predict Immunotherapy Response

The liquid biopsy uses cell-free DNA to map tumor microenvironments, helping identify which patients may benefit from immunotherapy across multiple cancer types
byToday's Clinical Lab
The FDA is seeking information from patients, clinicians, researchers, and other stakeholders on priority disease areas and potential candidates for drug repurposing.
|2 min read

FDA Launches Initiative to Advance Drug Repurposing for Unmet Medical Needs

The agency is particularly focused on new uses to treat chronic or rare diseases, substance use disorders
byU.S. Food and Drug Administration
Visual depiction of genetic factors in cardiovascular disease risk assessment.
|2 min read

Mass General Brigham Validates Polygenic Risk Score Tool for Predicting 8 Cardiovascular Conditions

New integrated polygenic risk score test, now available across the US, may help identify patients at elevated inherited risk for cardiovascular disease before traditional clinical factors emerge
byToday's Clinical Lab
At the 31st Annual Executive War College, speakers highlighted how clinical laboratories are evolving into strategic leaders—driving integration, innovation, and system-wide performance across health care.
|3 min read

The Expanding Strategic Role of the Clinical Laboratory at the 31st Annual Executive War College

Once viewed as a support function, labs are now central to integration, performance improvement, and enterprise-wide decision-making
byJanette Wider
Dr. Damian Young, investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI) and director of the Center for Drug Discovery at Baylor College of Medicine, along with collaborators has been awarded a $6.7 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to develop new approaches to rapidly identify potential treatments for Alzheimer’s disease and related dementias with the goal of accelerating the discovery of new therapies.
|3 min read

Texas Children’s Launches Large-Scale Open Drug Discovery Platform for Alzheimer’s Therapies

The NIH-funded initiative combines high-throughput screening and AI, giving global researchers access to one of the largest Alzheimer’s discovery datasets
byTexas Children's Hospital
The collaboration also reflects growing interest in ctDNA-based assays as tools for more precise disease monitoring and personalized treatment strategies.
|2 min read

Quest Expands Haystack MRD ctDNA Testing in City of Hope Cancer Trials

A multi-site study will evaluate how a ctDNA assay may support residual disease detection and treatment monitoring in solid tumors
byToday's Clinical Lab
A major focus of the latest update is a restructuring of head and neck cancer protocols.
|2 min read

CAP Updates Cancer Protocols, Clarifies MMR/MSI Testing Discordance in New Article

The updates underscore shifts toward more standardized cancer reporting and more integrated interpretation of MMR/MSI testing in clinical decision-making
byMiriam Bergeret, MSc
The research was carried out by Carles López Mateu, María Gómez Mahiques, F. Javier Gil Terrón, Víctor Montosa i Micó, Juan M. García-Gómez and Elies Fuster García, in collaboration with researchers from Oslo University Hospital.
|2 min read

A New Biomarker Helps Assess the Aggressiveness of Glioblastoma

Developed by the ITACA BDSLab, it can identify different patterns of tumor growth and independently predict patient survival
byUniversitat Politècnica de València
The Administration’s budget request, released today, proposes a 12 percent reduction to the NIH budget.
|2 min read

AACR Calls on Congress to Once Again Summarily Reject the President’s Budget Proposal for NIH

The President’s FY2027 budget proposal includes devastating cuts of nearly $6 billion to NIH’s budget for lifesaving research
byAmerican Association for Cancer Research
Page 1 of 106
123456789

Sponsored

Social

Your Model From Our Experience: Cloud First Digital Pathology in a High-Volume Regional Laboratory  

Sponsored by
A clinician holds a AI chip surrounded by digital healthcare icons, representing the use of artificial intelligence in clinical diagnostics

Ensuring Compliance: How to Get AI Diagnostic Tools Approved for Clinical Practice

Sponsored by
Two researchers working in a diagnostic lab with advanced testing solutions

Cutting-Edge Gastrointestinal Pathogen Testing Technologies for Labs

Sponsored by
Screenshot

The Path to Absolute Quantification in Gene Expression

Sponsored by